Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy (Q37546096)

20 August 2017

1 reference

title

Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy (English)

1 reference

20 August 2017

0 references

1 reference

Hans-Gert Bernstein

1

1 reference

PubMed ID

19589054

20 August 2017

Johann Steiner

series ordinal

2

1 reference

PubMed ID

19589054

20 August 2017

Bernhard Bogerts

series ordinal

3

1 reference

20 August 2017

1 July 2009

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

20 August 2017

1 reference

20 August 2017

9

1 reference

20 August 2017

7

1 reference

20 August 2017

1059-1071

1 reference

Cerebral disconnectivity: an early event in schizophrenia

20 August 2017

1 reference

Alterations of white matter connectivity in first episode schizophrenia.

21 January 2018

1 reference

Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon?

21 January 2018

1 reference

Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia

21 January 2018

1 reference

Evidence for white matter abnormalities in schizophrenia

21 January 2018

1 reference

Meta-analysis of diffusion tensor imaging studies in schizophrenia

21 January 2018

1 reference

White matter and cognitive function in schizophrenia

21 January 2018

1 reference

Myelin staining of deep white matter in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and unipolar major depression

21 January 2018

1 reference

White matter changes in schizophrenia: evidence for myelin-related dysfunction

21 January 2018

1 reference

Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium.

21 January 2018

1 reference

Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia

21 January 2018

1 reference

Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia.

21 January 2018

1 reference

Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus.

21 January 2018

1 reference

Stereologic investigation of the posterior part of the hippocampus in schizophrenia.

21 January 2018

1 reference

Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders.

21 January 2018

1 reference

Deficit of pericapillary oligodendrocytes in the prefrontal cortex in schizophrenia.

21 January 2018

1 reference

The role of oligodendrocyte pathology in schizophrenia.

21 January 2018

1 reference

The ultrastructure of lymphocytes in schizophrenia.

21 January 2018

1 reference

Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis

21 January 2018

1 reference

Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys

21 January 2018

1 reference

Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia

21 January 2018

1 reference

Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia

21 January 2018

1 reference

Oligodendrocyte dysfunction in schizophrenia and bipolar disorder

21 January 2018

1 reference

Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients.

21 January 2018

1 reference

Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study

21 January 2018

1 reference

Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness.

21 January 2018

1 reference

Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins.

21 January 2018

1 reference

Altered myelination of the hippocampal formation in subjects with schizophrenia and bipolar disorder.

21 January 2018

1 reference

Introduction to the special section: Myelin and oligodendrocyte abnormalities in schizophrenia.

21 January 2018

1 reference

Human QKI, a potential regulator of mRNA expression of human oligodendrocyte-related genes involved in schizophrenia

21 January 2018

1 reference

Human QKI, a new candidate gene for schizophrenia involved in myelination.

21 January 2018

1 reference

The myelin-pathogenesis puzzle in schizophrenia: a literature review

21 January 2018

1 reference

Genetic study of the myelin oligodendrocyte glycoprotein (MOG) gene in schizophrenia.

21 January 2018

1 reference

A family-based association study of the myelin-associated glycoprotein and 2',3'-cyclic nucleotide 3'-phosphodiesterase genes with schizophrenia.

21 January 2018

1 reference

Polymorphisms of Transferrin gene are associated with schizophrenia in Chinese Han population.

21 January 2018

1 reference

Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia

21 January 2018

1 reference

Oligodendroglial abnormalities in schizophrenia, mood disorders and substance abuse. Comorbidity, shared traits, or molecular phenocopies?

21 January 2018

1 reference

Mechanisms of neuregulin action

21 January 2018

1 reference

Immunohistochemical evidence for impaired neuregulin-1 signaling in the prefrontal cortex in schizophrenia and in unipolar depression.

21 January 2018

1 reference

Localization of neuregulin-1alpha (heregulin-alpha) and one of its receptors, ErbB-4 tyrosine kinase, in developing and adult human brain.

21 January 2018

1 reference

ErbB receptors and the development of the nervous system

21 January 2018

1 reference

Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients

21 January 2018

1 reference

Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia

21 January 2018

1 reference

Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders

21 January 2018

1 reference

Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia

21 January 2018

1 reference

Expression of oligodendrocyte-associated genes in dorsolateral prefrontal cortex of patients with schizophrenia

21 January 2018

1 reference

Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3'-UTR.

21 January 2018

1 reference

Evidence for a wide extra-astrocytic distribution of S100B in human brain

21 January 2018

1 reference

S100B is expressed in, and released from, OLN-93 oligodendrocytes: Influence of serum and glucose deprivation.

21 January 2018

1 reference

Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia.

21 January 2018

1 reference

Dopamine D2 and D3 receptor agonists limit oligodendrocyte injury caused by glutamate oxidative stress and oxygen/glucose deprivation

21 January 2018

1 reference

Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability.

21 January 2018

1 reference

Why does remyelination fail in multiple sclerosis?

21 January 2018

1 reference

Remyelination in the CNS: from biology to therapy

21 January 2018

1 reference

Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency

21 January 2018

1 reference

Cytokines and myelination in the central nervous system.

21 January 2018

1 reference

Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission

21 January 2018

1 reference

Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review

21 January 2018

1 reference

Restoration of FcRgamma/Fyn signaling repairs central nervous system demyelination.

21 January 2018

1 reference

21 January 2018

1 reference

Insulin-like growth factor system regulates oligodendroglial cell behavior: therapeutic potential in CNS.

21 January 2018

1 reference

Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes.

21 January 2018

1 reference

The problem of astrocyte identity

21 January 2018

1 reference

The form of velate astrocytes in the cerebellar cortex of monkey and rat: High voltage electron microscopy of rapid Golgi preparations

21 January 2018

1 reference

Preferential histochemical staining of protoplasmic and fibrous astrocytes in rat CNS with GFAP antibodies using different fixatives

21 January 2018

1 reference

Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders.

21 January 2018

1 reference

Glial cell abnormalities in major psychiatric disorders: the evidence and implications

21 January 2018

1 reference

Gliosis in schizophrenia: a survey

21 January 2018

1 reference

No evidence for astrogliosis in brains of schizophrenic patients. A post-mortem study.

21 January 2018

1 reference

A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis.

21 January 2018

1 reference

Cell loss in the hippocampus of schizophrenics

21 January 2018

1 reference

Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics.

21 January 2018

1 reference

Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia.

21 January 2018

1 reference

Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia.

21 January 2018

1 reference

Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia

21 January 2018

1 reference

Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia

21 January 2018

1 reference

Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder.

21 January 2018

1 reference

Neuron-astrocyte signaling in the development and plasticity of neural circuits

21 January 2018

1 reference

GLIA: listening and talking to the synapse

21 January 2018

1 reference

Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

21 January 2018

1 reference

Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients

21 January 2018

1 reference

Tryptophan breakdown pathway in bipolar mania.

21 January 2018

1 reference

The astrocyte surface NAAG receptor and NAAG peptidase signaling complex as a therapeutic target

21 January 2018

1 reference

Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia

21 January 2018

1 reference

Selective decreases in MAO-B activity in post-mortem brains from schizophrenic patients with type II syndrome.

21 January 2018

1 reference

How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?

21 January 2018

1 reference

Rheumatoid arthritis and schizophrenia: a negative association at a dimensional level

21 January 2018

1 reference

The association of the HLA in patients with schizophrenia, schizoaffective disorder, and in their biological relatives.

21 January 2018

1 reference

Cytomegalovirus and schizophrenia

21 January 2018

1 reference

Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis

21 January 2018

1 reference

Prenatal exposure to maternal genital and reproductive infections and adult schizophrenia.

21 January 2018

1 reference

The risk for schizophrenia from childhood and adult infections

21 January 2018

1 reference

Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia.

21 January 2018

1 reference

Cytokines in schizophrenia and the effects of antipsychotic drugs

21 January 2018

1 reference

Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications

21 January 2018

1 reference

Herpesviruses and Toxoplasma gondii in orbital frontal cortex of psychiatric patients

21 January 2018

1 reference

Evidence for activation of microglia in patients with psychiatric illnesses.

21 January 2018

1 reference

Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia.

21 January 2018

1 reference

Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia.

21 January 2018

1 reference

Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide.

21 January 2018

1 reference

Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization.

21 January 2018

1 reference

Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases

21 January 2018

1 reference

Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study.

21 January 2018

1 reference

Possible antipsychotic effects of minocycline in patients with schizophrenia.

21 January 2018

1 reference

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy

21 January 2018

1 reference

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

Clinical effects of COX-2 inhibitors on cognition in schizophrenia.

21 January 2018

1 reference

Celecoxib augmentation of continuously ill patients with schizophrenia.

21 January 2018

1 reference

Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease.

21 January 2018

1 reference

Convergent Evidence for 2′,3′-Cyclic Nucleotide 3′-Phosphodiesterase as a Possible Susceptibility Gene for Schizophrenia

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.09.59

1 reference

20 August 2017

1 reference

PubMed ID

19589054